Improved patient surveillance and data acquisition with a third generation implantable cardioverter defibrillator.

Thirteen patients were implanted with the Telectronics 4210 ATP implantable cardioverter defibrillator (ICD) for ventricular tachycardia or ventricular fibrillation. This device has multiprogrammable antitachycardia pacing, bradycardia pacing, and shock therapies. In addition, there is extensive data logging and ECG snapshot capability for arrhythmia confirmation and response to therapy. These features permit easy retrieval of all detected and treated events, whatever the eventual outcome. In this study, the data logged at predischarge electrophysiological testing was compared to the data recorded in a standard manner. The bulk of the data, however, was derived from long-term follow-up of spontaneous events over a mean period of 203 days (range 154-257). During this period, a total of 6,193 arrhythmia detections were made: 20 were classified as ventricular fibrillation, and 6,173 as ventricular tachycardia. The vast majority of these (93%) terminated spontaneously without ICD intervention (5,738), underscoring the benefit of a standard second confirmation prior to therapy delivery (noncommitted system). There were 394 arrhythmia episodes treated with antitachycardia pacing; of these a total of 8.3% accelerated to either more rapid ventricular tachycardia or ventricular fibrillation (4.3% and 4.0%, respectively). Events were reported in an "episode log" format, listing all arrhythmia detections with time/date annotation; or in a "sense history" format, detailing each episode from start to conclusion. These data demonstrate that this advanced, "tiered" ICD with data recall contributes to better patient management, and permits a more tailored termination prescription for the individual patient.